Autolus Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Autolus Therapeutics kazanç ve gelirin sırasıyla yıllık 50.6% ve 59% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 52.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -311.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

50.6%

Kazanç büyüme oranı

52.4%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.4%
Gelir büyüme oranı	59.0%
Gelecekteki özkaynak getirisi	-311.9%
Analist kapsamı	Good
Son güncelleme	19 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Nov 21

Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity

May 14

We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Nov 06

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Jun 26

We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Mar 09

Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Dec 12

Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy

Oct 12

Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching

Aug 17

Autolus Therapeutics Q2 2022 Earnings Preview

Aug 03

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Apr 19

We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully

Dec 15

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:AUTL - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	147	-129	-91	-73	6
12/31/2025	58	-201	-150	-126	8
12/31/2024	17	-233	-274	-208	8
9/30/2024	10	-270	-206	-193	N/A
6/30/2024	10	-234	-161	-157	N/A
3/31/2024	10	-221	-152	-144	N/A
12/31/2023	2	-208	-157	-146	N/A
9/30/2023	6	-158	-145	-135	N/A
6/30/2023	7	-155	-142	-127	N/A
3/31/2023	7	-152	-133	-120	N/A
12/31/2022	6	-149	-123	-112	N/A
9/30/2022	3	-164	-119	-107	N/A
6/30/2022	1	-155	-119	-110	N/A
3/31/2022	2	-146	-123	-116	N/A
12/31/2021	2	-142	-127	-118	N/A
9/30/2021	3	-143	-149	-136	N/A
6/30/2021	3	-147	-154	-141	N/A
3/31/2021	2	-145	-145	-131	N/A
12/31/2020	2	-142	-132	-118	N/A
9/30/2020	2	-140	-134	-123	N/A
6/30/2020	1	-130	-120	-109	N/A
3/31/2020	1	-127	-113	-99	N/A
12/31/2019	3	-124	-120	-101	N/A
9/30/2019	3	-104	-109	-88	N/A
6/30/2019	3	-89	-93	-72	N/A
3/31/2019	3	-68	-76	-61	N/A
12/31/2018	1	-58	-56	-43	N/A
9/30/2018	1	-45	-41	-32	N/A
6/30/2018	1	-41	N/A	N/A	N/A
3/31/2018	2	-38	N/A	N/A	N/A
12/31/2017	2	-29	N/A	N/A	N/A
9/30/2017	2	-20	N/A	-16	N/A
9/30/2016	1	-13	N/A	-10	N/A
9/30/2015	0	-7	N/A	-3	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: AUTL önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: AUTL önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: AUTL önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: AUTL şirketinin gelirinin (yıllık 59% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: AUTL şirketinin gelirinin (yıllık 59% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: AUTL 3 yıl içinde kârsız olması bekleniyor.

Autolus Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates fall by 16%

Consensus revenue estimates fall by 15%

Consensus revenue estimates decrease by 24%, EPS upgraded

Consensus revenue estimates increase by 23%

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 11%

Recent updates

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Consensus revenue estimates fall by 16%

Autolus Therapeutics plc Announces FDA Approval of AUCATZYL for Adults with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL)

New minor risk - Share price stability

Autolus Therapeutics plc to Report Q3, 2024 Results on Nov 12, 2024

Autolus Therapeutics plc Appoints Matthias Will as Chief Development Officer, Effective September 30, 2024

Founder notifies of intention to sell stock

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case

Autolus Therapeutics plc Presents Clinical Data Update at the Society of Hematologic Oncology Annual Meeting

Consensus revenue estimates fall by 15%

Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?

High number of new directors

Autolus Therapeutics: Major Inflection Point On The Horizon

Autolus Therapeutics plc to Report Q2, 2024 Results on Aug 08, 2024

Autolus Therapeutics plc to Present Three Clinical Data Updates on Obecabtagene Autoleucel (obe-cel) in Relapsed/Refractory B-Cell Acute L-Cell Acute Lymphoblastic Leukemia (All) Patients at the 2024 European Hematology Association (EHA) Congress

Autolus Therapeutics plc, Annual General Meeting, Jun 28, 2024

Autolus Therapeutics plc Presents Long-Term Follow-Up and Additional Data Analysis of Pivotal Phase 2 FELIX Study of Obecabtagene Autoleucel in an Oral Presentation at ASCO

Autolus Therapeutics plc announced delayed 10-Q filing

Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity

High number of new directors

Autolus Therapeutics plc to Report Q1, 2024 Results on May 14, 2024

Consensus revenue estimates decrease by 24%, EPS upgraded

Autolus Therapeutics Announces Changes to its Board of Directors

New major risk - Shareholder dilution

Consensus revenue estimates increase by 23%

Full year 2023 earnings released: US$1.20 loss per share (vs US$1.57 loss in FY 2022)

Autolus Therapeutics plc Receives Medicines and Healthcare Products Regulatory Agency (MHRA) Certification for Nucleus Commercial Manufacturing Site

Autolus Therapeutics plc Receives Medicines and Healthcare Products Regulatory Agency (MHRA) Certification for Nucleus Commercial Manufacturing Site

Autolus Therapeutics plc to Report Fiscal Year 2023 Results on Mar 14, 2024

Forecast to breakeven in 2026

New minor risk - Shareholder dilution

Autolus Therapeutics plc has completed a Follow-on Equity Offering in the amount of $350.000016 million.

Autolus Therapeutics plc announced that it expects to receive $220.000002 million in funding from BioNTech SE

High number of new directors

Consensus revenue estimates decrease by 11%

Autolus Therapeutics plc Announces Acceptance of Biologics License Application for Obecabtagene Autoleucel as Potential Treatment for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia

Autolus Therapeutics plc Announces the Appointment of Robert W. Azelby to Its Board of Directors

Autolus Therapeutics plc Announces Changes to Its Board of Directors, Effective December 31, 2023

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for Obecabtagene Autoleucel for Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for Obecabtagene Autoleucel for Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia

Consensus estimates of losses per share improve by 10%

We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Consensus revenue estimates increase by 11%

Autolus Therapeutics plc to Report Q3, 2023 Results on Nov 02, 2023

Price target increased by 9.1% to US$7.98

Autolus Therapeutics plc Announces Data from Auto1/22 Trial in Pediatric Acute Lymphoblastic Leukemia Published in the Journal Blood

Autolus Therapeutics plc Announces CFO Changes

Autolus Therapeutics Announces Publication in Nature Medicine on Obe-Cel in Pediatric Acute Lymphoblastic Leukemia

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Autolus Therapeutics plc Appoints Robert Iannone as Non-Executive Director

Autolus Therapeutics plc Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Autolus Therapeutics plc, Annual General Meeting, Jun 30, 2023

Consensus EPS estimates upgraded to US$0.87 loss

Autolus Therapeutics plc Presents Positive Results from Pivotal Phase 2 Felix Study in Adult R/R B-All At Asco

Consensus revenue estimates decrease by 55%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 65%

Consensus revenue estimates decrease by 90%, EPS upgraded

We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Autolus Therapeutics plc to Report Q4, 2022 Results on Mar 07, 2023

Autolus Therapeutics plc Announces Board Changes

Consensus forecasts updated

Price target decreased to US$9.40

Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Consensus revenue estimates increase by 281%

Autolus Therapeutics plc Announces Pivotal Phase 2 Felix Clinical Trial Has Met Primary Endpoint At Interim Analysis

Price target decreased to US$10.19

Consensus revenue estimates increase by 979%